{"id":"ivabradine","rwe":[{"pmid":"41901349","year":"2026","title":"Ivabradine Attenuates Experimental Hepatic Fibrosis by Modulating Inflammatory and Apoptotic Signaling Pathways.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41863817","year":"2026","title":"Comparative Effectiveness of Ivabradine Versus Digoxin in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study.","finding":"","journal":"Cardiorenal medicine","studyType":"Clinical Study"},{"pmid":"41845224","year":"2026","title":"Potential use of ivabradine in postoperative junctional ectopic tachycardia: a systematic review and single-arm meta-analysis.","finding":"","journal":"BMC cardiovascular disorders","studyType":"Clinical Study"},{"pmid":"41823892","year":"2026","title":"Cost-effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective.","finding":"","journal":"Value in health regional issues","studyType":"Clinical Study"},{"pmid":"41817681","year":"2026","title":"Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review.","finding":"","journal":"Journal of comparative effectiveness research","studyType":"Clinical Study"}],"_fda":{"id":"32d59c63-db88-3e0c-e063-6294a90acd9f","set_id":"236cc914-7eef-600c-e063-6394a90a4bd1","openfda":{"unii":["TP19837BZK"],"route":["ORAL"],"rxcui":["1649485","1649493"],"spl_id":["32d59c63-db88-3e0c-e063-6294a90acd9f"],"brand_name":["IVABRADINE"],"spl_set_id":["236cc914-7eef-600c-e063-6394a90a4bd1"],"package_ndc":["51407-592-60","51407-593-60"],"product_ndc":["51407-592","51407-593"],"generic_name":["IVABRADINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["IVABRADINE HYDROCHLORIDE"],"manufacturer_name":["Golden State Medical Supply, Inc."],"application_number":["ANDA214051"],"original_packager_product_ndc":["50742-362","50742-363"]},"version":"2","pregnancy":["8.1 Pregnancy Risk Summary Based on findings in animals, ivabradine tablets may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of ivabradine tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies, oral administration of ivabradine to pregnant rats during organogenesis at a dosage providing 1 to 3 times the human exposure (AUC 0-24hr ) at the MRHD resulted in embryo-fetal toxicity and teratogenicity manifested as abnormal shape of the heart, interventricular septal defect, and complex anomalies of primary arteries. Increased post-natal mortality was associated with these teratogenic effects in rats. In pregnant rabbits, increased post-implantation loss was noted at an exposure (AUC 0-24hr ) 5 times the human exposure at the MRHD. Lower doses were not tested in rabbits. The background risk of major birth defects for the indicated population is unknown. The estimated background risk of major birth defects in the U.S. general population is 2 to 4%, however, and the estimated risk of miscarriage is 15 to 20% in clinically recognized pregnancies. Advise a pregnant woman of the potential risk to the fetus. Clinical Considerations Disease-associated Maternal and/or Embryo-fetal Risk Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Pregnant patients with left ventricular ejection fraction less than 35% on maximally tolerated doses of beta-blockers may be particularly heart rate dependent for augmenting cardiac output. Therefore, pregnant patients who are started on ivabradine tablets, especially during the first trimester, should be followed closely for destabilization of their congestive heart failure that could result from heart rate slowing. Monitor pregnant women with chronic heart failure in 3 rd trimester of pregnancy for preterm birth. Data Animal Data In pregnant rats, oral administration of ivabradine during the period of organogenesis (gestation day 6-15) at doses of 2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and teratogenic effects. Increased intrauterine and post-natal mortality and cardiac malformations were observed at doses ≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0-24hr ). Teratogenic effects including interventricular septal defect and complex anomalies of major arteries were observed at doses ≥ 4.6mg/kg/day (approximately 3 times the human exposure at the MRHD based on AUC 0-24hr ). In pregnant rabbits, oral administration of ivabradine during the period of organogenesis (gestation day 6-18) at doses of 7, 14, or 28 mg/kg/day resulted in fetal toxicity and teratogenicity. Treatment with all doses ≥ 7 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0-24hr ) caused an increase in post-implantation loss. At the high dose of 28 mg/kg/day (approximately 15 times the human exposure at the MRHD based on AUC 0-24hr ), reduced fetal and placental weights were observed, and evidence of teratogenicity (ectrodactylia observed in 2 of 148 fetuses from 2 of 18 litters) was demonstrated. In the pre- and post-natal study, pregnant rats received oral administration of ivabradine at doses of 2.5, 7, or 20 mg/kg/day from gestation day 6 to lactation day 20. Increased post-natal mortality associated with cardiac teratogenic findings was observed in the F1 pups delivered by dams treated at the high dose (approximately 15 times the human exposure at the MRHD based on AUC 0-24hr )."],"overdosage":["10 OVERDOSAGE Overdose may lead to severe and prolonged bradycardia. In the event of bradycardia with poor hemodynamic tolerance, temporary cardiac pacing may be required. Supportive treatment, including intravenous (IV) fluids, atropine, and intravenous beta-stimulating agents such as isoproterenol, may be considered."],"description":["11 DESCRIPTION Ivabradine tablets contains ivabradine as the active pharmaceutical ingredient. Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the I f current, resulting in heart rate reduction with no effect on ventricular repolarization and no effects on myocardial contractility. The chemical name for ivabradine hydrochloride is: 3-(3-{[((7 S )-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl)methyl] methyl amino} propyl)-1,3,4,5-tetrahydro-7,8-dimethoxy-2 H -3-benzazepin-2-one,hydrochloride.The molecular formula is C 27 H 36 N 2 O 5 · HCl, and the molecular weight (free base +HCl) is 505.1 (468.6 + 36.5). The chemical structure of ivabradine is shown in Figure 1. Figure 1. Chemical Structure of Ivabradine Tablets Ivabradine tablets are supplied in 5 mg and 7.5 mg tablets for oral administration. The tablets contain 5 mg and 7.5 mg of ivabradine, as active ingredient, equivalent to 5.39 mg and 8.09 mg of ivabradine hydrochloride, respectively. The tablets contain the following inactive ingredients: lactose monohydrate, maltodextrin, maize starch b, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol 4000, yellow iron oxide and red iron oxide. Image"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Ivabradine tablets 5 mg tablets are formulated as Light salmon-colored, Capsule-shaped, film-coated scored tablets debossed with \"I5\" divided by the score on one side and plain on the other. They are supplied as follows: Bottles of 60 tablets with child-resistant closure, (NDC 51407-592-60) Ivabradine tablets 7.5 mg tablets are formulated as Light salmon-colored, Round-shaped, film-coated tablets debossed with \"I\" on one side and \"7.5\" on the other side. They are supplied as follows: Bottles of 60 tablets with child-resistant closure, (NDC 51407-593-60) Storage Store ivabradine tablets at 25ºC (77ºF); excursions permitted to 15ºC - 30ºC (59ºF -86ºF) [see USP Controlled Room Temperature]."],"spl_medguide":["SPL MEDGUIDE Dispense with Medication Guide available at: www.ingenus.com/medguide/ivabradine-tablets.pdf This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised: 09/2023 MEDICATION GUIDE Ivabradine (eye VAB ra deen) Tablets What is the most important information I should know about ivabradine tablets? Ivabradine tablets may cause serious side effects in adults and children, including: ● Harm to an unborn baby. Females who are able to get pregnant: ○ Must use effective birth control during treatment with ivabradine tablets. ○ Tell your doctor right away if you become pregnant during treatment with ivabradine tablets. ● Increased risk of irregular or rapid heartbeat (atrial fibrillation or heart rhythm problems). Tell your doctor if you feel any of the following symptoms of an irregular or rapid heartbeat: ○ heart is pounding or racing (palpitations). ○ chest pressure. ○ worsened shortness of breath. ○ near fainting or fainting. ● Slower than normal heart rate (bradycardia). Tell your doctor if you have: ○ a slowing of heart rate, or ○ symptoms of a slow heart rate such as dizziness, fatigue, lack of energy. In young children signs and symptoms of slow heart rate may include: poor feeding, difficulty breathing or turning blue What is ivabradine tablets ? Ivabradine tablets is a prescription medicine used: ● to treat adults who have chronic (lasting a long time) heart failure, with symptoms, to reduce their risk of hospitalization for worsening heart failure. Who should not take ivabradine tablets ? Do not take ivabradine tablets if you have: ● symptoms of heart failure that recently worsened ● very low blood pressure (hypotension) ● certain heart conditions: sick sinus syndrome, sinoatrial block, or 3 rd degree atrioventricular block ● a slow resting heart rate before treatment with ivabradine tablets. Ask your doctor what a slow resting heart rate is for you. ● certain liver problems ● been prescribed any medicines that can increase the effects of ivabradine tablets. Ask your doctor if you are not sure if you have any of the medical conditions listed above. What should I tell my doctor before taking ivabradine tablets ? Before you take ivabradine tablets, tell your doctor about all of your medical conditions, Including if you: ● have any other heart problems, including heart rhythm problems, a slow heart rate, or a heart conduction problem. ● are breastfeeding or planning to breastfeed. It is not known if ivabradine passes into breast milk. You and your doctor should decide if you will take ivabradine tablets or breastfeed; do not do both. ● are pregnant or planning to become pregnant. See \"What is the most important information I should know about ivabradine tablets ? - Harm to an unborn baby\" section. Tell your doctor about all the medicines you take, including prescription and over the counter medicines, vitamins, and herbal supplements. Ivabradine tablets may affect the way other medicines work, and other medicines may affect how ivabradine tablets works. This could cause serious side effects. How should you take ivabradine tablets ? ● Take ivabradine tablets exactly as your doctor tells you. ● Do not stop taking ivabradine tablets without talking with your doctor. ● Ivabradine tablets comes as a tablet. ○ Tell your doctor if you have trouble swallowing tablets. ○ Your doctor may change your dose of ivabradine tablets during treatment. ● Take ivabradine tablets 2 times each day with food. ● If you miss a dose of ivabradine tablets, do not give another dose. Give the next dose at the usual time. ● If you or your child take too much ivabradine tablets, call your doctor or go to the nearest emergency room right away. What should you avoid while taking ivabradine tablets ? ● Avoid drinking grapefruit juice and taking St. John's wort during treatment with ivabradine tablets. These can affect the way ivabradine tablets works and may cause serious side effects. What are the possible side effects of ivabradine tablets ? Ivabradine tablets may cause serious side effects. See \"What is the most important information I should know about ivabradine tablets ?\" The most common side effects of ivabradine tablets are: ● increased blood pressure ● temporary brightness in part of your field of vision. This is usually caused by sudden changes in light (luminous phenomena). This brightness usually happens within the first 2 months of treatment with ivabradine tablets and may go away during or after treatment with ivabradine tablets. Be careful when driving or operating machinery where sudden changes in light can happen, especially when driving at night. These are not all the side effects of ivabradine tablets. Ask your doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store ivabradine tablets ? ● Store ivabradine tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep ivabradine tablets and all medicines out of the reach of children. General information about the safe and effective use of ivabradine tablets . Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ivabradine tablets for a condition for which it was not prescribed. Do not give ivabradine tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information about ivabradine tablets that is written for health professionals. What are the ingredients in ivabradine tablets ? Active ingredient: ivabradine Inactive ingredients: Tablet: lactose monohydrate, maltodextrin, maize starch b, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol 4000, yellow iron oxide and red iron oxide. Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32811-7193 Made in India For more information contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 Marketed by: GSMS, Inc. Camarillo, CA 93012 USA Image"],"geriatric_use":["8.5 Geriatric Use No pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population. However, ivabradine tablets has only been studied in a limited number of patients ≥ 75 years of age."],"pediatric_use":["8.4 Pediatric Use The safety and efficacy of ivabradine tablets have not been established in patients less than 6 months of age."],"effective_time":"20250415","clinical_studies":["14 CLINICAL STUDIES 14.1 Heart Failure in Adult Patients SHIFT The Systolic Heart failure treatment with the I f inhibitor ivabradine Trial (SHIFT) was a randomized, double-blind trial comparing ivabradine tablets and placebo in 6558 adult patients with stable New York Heart Association (NYHA) class II to IV heart failure, left ventricular ejection fraction ≤ 35%, and resting heart rate ≥ 70 bpm. Patients had to have been clinically stable for at least 4 weeks on an optimized and stable clinical regimen, which included maximally tolerated doses of beta-blockers and, in most cases, ACE inhibitors or ARBs, spironolactone, and diuretics, with fluid retention and symptoms of congestion minimized. Patients had to have been hospitalized for heart failure within 12 months prior to study entry. The underlying cause of CHF was coronary artery disease in 68% of patients. At baseline, approximately 49% of randomized subjects were NYHA class II, 50% were NYHA class III, and 2% were NYHA class IV. The mean left ventricular ejection fraction was 29%. All subjects were initiated on ivabradine tablets 5 mg (or matching placebo) twice daily and the dose was increased to 7.5 mg twice daily or decreased to 2.5 mg twice daily to maintain the resting heart rate between 50 and 60 bpm, as tolerated. The primary endpoint was a composite of the first occurrence of either hospitalization for worsening heart failure or cardiovascular death. Most patients (89%) were taking beta-blockers, with 26% on guideline-defined target daily doses. The main reasons for not receiving the target beta-blocker doses at baseline were hypotension (45% of patients not at target), fatigue (32%), dyspnea (14%), dizziness (12%), history of cardiac decompensation (9%), and bradycardia (6%). For the 11% of patients not receiving any beta-blocker at baseline, the main reasons were chronic obstructive pulmonary disease, hypotension, and asthma. Most patients were also taking ACE inhibitors and/or angiotensin II antagonists (91%), diuretics (83%), and anti-aldosterone agents (60%). Few patients had an implantable cardioverter-defibrillator (ICD) (3.2%) or a cardiac resynchronization therapy (CRT) device (1.1%). Median follow-up was 22.9 months. At 1 month, 63%, 26%, and 8% of ivabradine tablets -treated patients were taking 7.5, 5, and 2.5 mg BID, whereas 3% had withdrawn from the drug, primarily for bradycardia. SHIFT demonstrated that ivabradine tablets reduced the risk of the combined endpoint of hospitalization for worsening heart failure or cardiovascular death based on a time-to-event analysis (hazard ratio: 0.82, 95% confidence interval [CI]: 0.75, 0.90, p < 0.0001) (Table 3). The treatment effect reflected only a reduction in the risk of hospitalization for worsening heart failure; there was no favorable effect on the mortality component of the primary endpoint. In the overall treatment population, ivabradine tablets had no statistically significant benefit on cardiovascular death. Table 3. SHIFT – Incidence of the Primary Composite Endpoint and Components a Patients who died on the same calendar day as their first hospitalization for worsening heart failure are counted under cardiovascular death. b Analyses of the components of the primary composite endpoint were not prospectively planned to be adjusted for multiplicity. N: number of patients at risk; n: number of patients having experienced the endpoint; %: incidence rate = (n/N) × 100; % PY: annual incidence rate = (n/number of patient-years) × 100; CI:Confidence interval Endpoint Ivabradine tablets (N = 3,241) % Placebo (N = 3,264) % Hazard n % PY n % PY Ratio [95%CI] p-value Primary composite endpoint: 793 24.5 14.5 937 28.7 17.7 0.82 [0.75 , 0.90] < 0.0001 Time to first hospitalization for worsening heart failure or cardiovascular death a 505 15.6 9.2 660 20.2 12.5 Hospitalization for worsening heart failure Cardiovascular death as first event 288 8.9 4.8 277 8.5 4.7 Subjects with events at any Time Hospitalization for worsening heart failure b 514 15.9 9.4 672 20.6 12.7 0.74 [0.66 , 0.83] Cardiovascular death b 449 13.9 7.5 491 15.0 8.3 0.91 [0.80 , 1.03] The hazard ratio between treatment groups (ivabradine/placebo) was estimated based on an adjusted Cox proportional hazards model with beta-blocker intake at randomization (yes/no) as a covariate; p-value: Wald test The Kaplan-Meier curve (Figure 3) shows time to first occurrence of the primary composite endpoint of hospitalization for worsening heart failure or cardiovascular death in the overall study. Figure 3. SHIFT: Time to First Event of Primary Composite Endpoint A wide range of demographic characteristics, baseline disease characteristics, and baseline concomitant medications were examined for their influence on outcomes. Many of these results are shown in Figure 4. Such analyses must be interpreted cautiously, as differences can reflect the play of chance among a large number of analyses. Most of the results show effects consistent with the overall study result. Ivabradine tablets benefit on the primary endpoint in SHIFT appeared to decrease as the dose of beta-blockers increased, with little if any benefit demonstrated in patients taking guideline-defined target doses of beta-blockers. Figure 4. Effect of Treatment on Primary Composite Endpoint in Subgroups Note: The figure above presents effects in various subgroups, all of which are baseline characteristics. The 95% confidence limits that are shown do not take into account the number of comparisons made and may not reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted. BEAUTIFUL and SIGNIFY: No benefit in stable coronary artery disease with or without stable heart failure The Morbidity-mortality Evaluation of the I f Inhibitor Ivabradine in Patients with Coronary Disease and Left Ventricular Dysfunction Trial (BEAUTIFUL) was a randomized, double-blind, placebo-controlled trial in 10,917 adult patients with coronary artery disease, impaired left ventricular systolic function (ejection fraction <40%) and resting heart rate ≥ 60 bpm. Patients had stable symptoms of heart failure and/or angina for at least 3 months and were receiving conventional cardiovascular medications at stable doses for at least 1 month. Beta-blocker therapy was not required, nor was there a protocol mandate to achieve any specific dosing targets for patients who were taking beta-blockers. Patients were randomized 1:1 to ivabradine tablets or placebo at an initial dose of 5 mg twice daily with the dose increased to 7.5 mg twice daily depending on resting heart rate and tolerability. The primary endpoint was the composite of time to first cardiovascular death, hospitalization for acute myocardial infarction, or hospitalization for new-onset or worsening heart failure. Most patients were NYHA class II (61.4%) or class III (23.2%) - none were class IV. Through a median follow-up of 19 months, ivabradine tablets did not significantly affect the primary composite endpoint (HR 1.00, 95% CI = 0.91, 1.10). The Study Assessing the Morbi-mortality Benefits of the I f Inhibitor Ivabradine in Patients with Coronary Artery Disease Trial (SIGNIFY) was a randomized, double-blind trial administering ivabradine tablets or placebo to 19,102 adult patients with stable coronary artery disease but without clinically evident heart failure (NYHA class I). Beta-blocker therapy was not required. Ivabradine tablets was initiated at a dose of 7.5 mg twice daily and the dose could be increased to as high as 10 mg twice daily or down-titrated to 5.0 mg twice daily to achieve a target heart rate of 55 to 60 bpm. The primary endpoint was a composite of the first occurrence of either cardiovascular death or myocardial infarction. Through a median follow-up of 24.1 months, ivabradine tablets did not significantly affect the primary composite endpoint (HR 1.08, 95% CI = 0.96, 1.20). Image Image"],"pharmacodynamics":["12.2 Pharmacodynamics Ivabradine tablets causes a dose-dependent reduction in heart rate. The size of the effect is dependent on the baseline heart rate (i.e., greater heart rate reduction occurs in subjects with higher baseline heart rate). At recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. Analysis of heart rate reduction vs. dose indicates a plateau effect at doses > 20 mg twice daily. In a study of subjects with preexisting conduction system disease (first- or second-degree AV block or left or right bundle branch block) requiring electrophysiologic study, IV ivabradine (0.20 mg/kg) administration slowed the overall heart rate by approximately 15 bpm, increased the PR interval (29 msec), and increased the AH interval (27 msec). Ivabradine tablets does not have negative inotropic effects. Ivabradine increases the uncorrected QT interval with heart rate slowing but does not cause rate-corrected prolongation of QT."],"pharmacokinetics":["12.3 Pharmacokinetics The peak concentration (C max ) and area under the plasma concentration time curve (AUC) are similar for ivabradine and S 18982 between oral solution and tablets for the same dose. Absorption and Bioavailability Following oral administration, peak plasma ivabradine concentrations are reached in approximately1 hour under fasting conditions. The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver. Food delays absorption by approximately 1 hour and increases plasma exposure by 20% to 40%. Ivabradine tablets should be taken with food [see Dosage and Administration (2) ]. Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L. Metabolism and Excretion The pharmacokinetics of ivabradine are linear over an oral dose range of 0.5 mg to 24 mg. Ivabradine is extensively metabolized in the liver and intestines by CYP3A4-mediated oxidation. The major metabolite is the N-desmethylated derivative (S 18982), which is equipotent to ivabradine and circulates at concentrations approximately 40% that of ivabradine. The N-desmethylated derivative is also metabolized by CYP3A4. Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours. The total clearance of ivabradine is 24 L/h, and renal clearance is approximately 4.2 L/h, with ~ 4% of an oral dose excreted unchanged in urine. The excretion of metabolites occurs to a similar extent via feces and urine. Drug Interactions The effects of coadministered drugs (CYP3A4 inhibitors, substrates, inducers, and other concomitantly administered drugs) on the pharmacokinetics of ivabradine tablets were studied in several single-and multiple dose studies. Pharmacokinetic measures indicating the magnitude of these interactions are presented in Figure 2. Figure 2. Impact of Coadministered Drugs on the Pharmacokinetics of Ivabradine tablets Digoxin exposure did not change when concomitantly administered with ivabradine. No dose adjustment is required when ivabradine is concomitantly administered with digoxin. Effect of Ivabradine on Metformin Pharmacokinetics Ivabradine, dosed at 10 mg twice daily to steady state, did not affect the pharmacokinetics of metformin (an organic cation transporter [OCT2] sensitive substrate). The geometric mean (90% confidence interval [CI]) ratios of C max and AUC inf of metformin, with and without ivabradine were 0.98 [0.83–1.15] and 1.02 [0.86–1.22], respectively. No dose adjustment is required for metformin when administered with ivabradine tablets. Specific Populations Age No pharmacokinetic differences (AUC or C max ) have been observed between elderly (≥ 65 years) or very elderly (≥ 75 years) patients and the overall patient population [see Use in Specific Populations (8.5) ]. Hepatic impairment In patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of ivabradine tablets were similar to that in patients with normal hepatic function. No data are available in patients with severe hepatic impairment (Child-Pugh C) [see Contraindications (4) ]. Renal impairment Renal impairment (creatinine clearance from 15 to 60 mL/min) has minimal effect on the pharmacokinetics of ivabradine tablets. No data are available for patients with creatinine clearance below 15 mL/min. Image"],"adverse_reactions":["6 ADVERSE REACTIONS Clinically significant adverse reactions that appear in other sections of the labeling include: Atrial Fibrillation [see Warnings and Precautions (5.2) ] Bradycardia and Conduction Disturbances [see Warnings and Precautions (5.3) ] Most common adverse reactions occurring in ≥ 1% of patients are bradycardia, hypertension, atrial fibrillation and luminous phenomena (phosphenes). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Patients with Heart Failure In SHIFT, safety was evaluated in 3,260 patients treated with ivabradine tablets and 3,278 patients given placebo. The median duration of ivabradine tablets exposure was 21.5 months. The most common adverse drug reactions in the SHIFT trial are shown in Table 2 [see Warnings and Precautions (5.2) , ( 5.3 )]. Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher on Ivabradine than Placebo occurring in > 1% on Ivabradine in SHIFT Ivabradine N = 3,260 Placebo N = 3,278 Bradycardia 10 % 2.2 % Hypertension, Blood Pressure Increased 8.9 % 7.8 % Atrial fibrillation 8.3 % 6.6 % Phosphenes, visual brightness 2.8 % 0.5 % Luminous Phenomena (Phosphenes) Phosphenes are phenomena described as a transiently enhanced brightness in a limited area of the visual field, halos, image decomposition (stroboscopic or kaleidoscopic effects), colored bright lights, or multiple images (retinal persistency). Phosphenes are usually triggered by sudden variations in light intensity. Ivabradine tablets can cause phosphenes, thought to be mediated through ivabradine tablets effects on retinal photoreceptors [see Clinical Pharmacology (12.1) ]. Onset is generally within the first 2 months of treatment, after which they may occur repeatedly. Phosphenes were generally reported to be of mild to moderate intensity and led to treatment discontinuation in < 1% of patients; most resolved during or after treatment. 6.2 Post marketing Experience Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure. The following adverse reactions have been identified in adults during post-approval use of ivabradine tablets: syncope, hypotension, torsade de pointes, ventricular fibrillation, ventricular tachycardia, angioedema, erythema, rash, pruritus, urticaria, vertigo, and diplopia, and visual impairment."],"contraindications":["4 CONTRAINDICATIONS Ivabradine tablets are contraindicated in patients with: Acute decompensated heart failure Clinically significant hypotension Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present Clinically significant bradycardia [see Warnings and Precautions (5.3) ] Severe hepatic impairment [see Use in Specific Populations (8.6) ] Pacemaker dependence (heart rate maintained exclusively by the pacemaker) [see Drug Interactions (7.3) ] Concomitant use of strong cytochrome P450 3A4 (CYP3A4) inhibitors [see Drug Interactions (7.1) ] Acute decompensated heart failure ( 4 ) Clinically significant hypotension ( 4 ) Sick sinus syndrome, sinoatrial block or 3 rd degree AV block, unless a functioning demand pacemaker is present ( 4 ) Clinically significant bradycardia ( 4 ) Severe hepatic impairment ( 4 ) Heart rate maintained exclusively by the pacemaker ( 4 ) In combination with strong cytochrome CYP3A4 inhibitors ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Avoid CYP3A4 inhibitors or inducers. ( 7.1 ) Negative chronotropes increase risk of bradycardia; monitor heart rate. ( 7.2 ) 7.1 Cytochrome P450-Based Interactions Ivabradine is primarily metabolized by CYP3A4. Concomitant use of CYP3A4 inhibitors increases ivabradine plasma concentrations and use of CYP3A4 inducers decreases them. Increased plasma concentrations may exacerbate bradycardia and conduction disturbances. The concomitant use of strong CYP3A4 inhibitors is contraindicated [see Contraindications (4) and Clinical Pharmacology (12.3) ]. Examples of strong CYP3A4 inhibitors include azole antifungals (e.g.,itraconazole), macrolide antibiotics (e.g., clarithromycin, telithromycin), HIV protease inhibitors (e.g.nelfinavir), and nefazodone. Avoid concomitant use of moderate CYP3A4 inhibitors when using ivabradine tablets. Examples of moderate CYP3A4 inhibitors include diltiazem, verapamil, and grapefruit juice [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3) ]. Avoid concomitant use of CYP3A4 inducers when using ivabradine tablets. Examples of CYP3A4 inducers include St. John's wort, rifampicin, barbiturates, and phenytoin [see Clinical Pharmacology (12.3) ]. 7.2 Negative Chronotropes Most patients receiving ivabradine tablets will also be treated with a beta-blocker. The risk of bradycardia increases with concomitant administration of drugs that slow heart rate (e.g., digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine tablets with other negative chronotropes. 7.3 Pacemakers in Adults Ivabradine tablets dosing is based on heart rate reduction, targeting a heart rate of 50 to 60 beats per minute in adults [see Dosage and Administration (2.1) ]. Patients with demand pacemakers set to a rate ≥ 60 beats per minute cannot achieve a target heart rate < 60 beats per minute, and these patients were excluded from clinical trials [see Clinical Studies (14.1) ]. The use of ivabradine tablets is not recommended in patients with demand pacemakers set to rates ≥ 60 beats per minute."],"spl_medguide_table":["
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Revised:09/2023
MEDICATION GUIDE Ivabradine (eye VAB ra deen) Tablets
What is the most important information I should know about ivabradine tablets? Ivabradine tabletsmay cause serious side effects in adults and children, including: ● Harm to an unborn baby.Females who are able to get pregnant: ○ Must use effective birth control during treatment with ivabradine tablets. ○ Tell your doctor right away if you become pregnant during treatment with ivabradine tablets. ● Increased risk of irregular or rapid heartbeat (atrial fibrillation or heart rhythm problems).Tell your doctor if you feel any of the following symptoms of an irregular or rapid heartbeat: ○ heart is pounding or racing (palpitations). ○ chest pressure. ○ worsened shortness of breath. ○ near fainting or fainting. ● Slower than normal heart rate (bradycardia).Tell your doctor if you have: ○ a slowing of heart rate, or ○ symptoms of a slow heart rate such as dizziness, fatigue, lack of energy. In young children signs and symptoms of slow heart rate may include: poor feeding, difficulty breathing or turning blue
What is ivabradinetablets? Ivabradine tablets is a prescription medicine used: ●to treat adults who have chronic (lasting a long time) heart failure, with symptoms, to reduce their risk of hospitalization for worsening heart failure.
Who should not take ivabradinetablets? Do nottake ivabradine tablets if you have: ●symptoms of heart failure that recently worsened ●very low blood pressure (hypotension) ●certain heart conditions: sick sinus syndrome, sinoatrial block, or 3 rddegree atrioventricular block ●a slow resting heart rate before treatment with ivabradine tablets. Ask your doctor what a slow resting heart rate is for you. ●certain liver problems ●been prescribed any medicines that can increase the effects of ivabradine tablets. Ask your doctor if you are not sure if you have any of the medical conditions listed above.
What should I tell my doctor before taking ivabradinetablets? Before you take ivabradine tablets, tell your doctor about all of your medical conditions, Including if you: ●have any other heart problems, including heart rhythm problems, a slow heart rate, or a heart conduction problem. ●are breastfeeding or planning to breastfeed. It is not known if ivabradine passes into breast milk. You and your doctor should decide if you will take ivabradine tablets or breastfeed; do not do both. ●are pregnant or planning to become pregnant. See "What is the most important information I should know about ivabradinetablets? - Harm to an unborn baby" section. Tell your doctor about all the medicines you take, including prescription and over the counter medicines, vitamins, and herbal supplements. Ivabradine tablets may affect the way other medicines work, and other medicines may affect how ivabradine tablets works. This could cause serious side effects.
How should you take ivabradinetablets? ●Take ivabradine tablets exactly as your doctor tells you. ● Do notstop taking ivabradine tablets without talking with your doctor. ●Ivabradine tablets comes as a tablet. ○ Tell your doctor if you have trouble swallowing tablets. ○ Your doctor may change your dose of ivabradine tablets during treatment. ●Take ivabradine tablets 2 times each day with food. ●If you miss a dose of ivabradine tablets, do not give another dose. Give the next dose at the usual time. ●If you or your child take too much ivabradine tablets, call your doctor or go to the nearest emergency room right away.
What should you avoid while taking ivabradinetablets? ●Avoid drinking grapefruit juice and taking St. John's wort during treatment with ivabradine tablets. These can affect the way ivabradine tablets works and may cause serious side effects.
What are the possible side effects of ivabradinetablets? Ivabradine tabletsmay cause serious side effects. See "What is the most important information I should know about ivabradinetablets?" The most common side effects of ivabradine tablets are: ●increased blood pressure ●temporary brightness in part of your field of vision. This is usually caused by sudden changes in light (luminous phenomena). This brightness usually happens within the first 2 months of treatment with ivabradine tablets and may go away during or after treatment with ivabradine tablets. Be careful when driving or operating machinery where sudden changes in light can happen, especially when driving at night. These are not all the side effects of ivabradine tablets. Ask your doctor or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store ivabradinetablets? ●Store ivabradine tablets at room temperature between 68°F to 77°F (20°C to 25°C). Keep ivabradinetabletsand all medicines out of the reach of children.
General information about the safe and effective use of ivabradinetablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ivabradine tablets for a condition for which it was not prescribed. Do not give ivabradine tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your doctor or pharmacist for information about ivabradine tablets that is written for health professionals.
What are the ingredients in ivabradinetablets? Active ingredient:ivabradine Inactive ingredients: Tablet:lactose monohydrate, maltodextrin, maize starch b, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, polyethylene glycol 4000, yellow iron oxide and red iron oxide. Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32811-7193 Made in India For more information contact Ingenus Pharmaceuticals, LLC at 1-877-748-1970 Marketed by:GSMS, Inc.Camarillo, CA 93012 USA
"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Ivabradine tablets blocks the hyperpolarization-activated cyclic nucleotide-gated (HCN) channel responsible for the cardiac pacemaker I f current, which regulates heart rate. In clinical electrophysiology studies, the cardiac effects were most pronounced in the sinoatrial (SA) node, but prolongation of the AH interval has occurred as has PR interval prolongation. There was no effect on ventricular repolarization and no effects on myocardial contractility [see Clinical Pharmacology (12.2) ]. Ivabradine tablets can also inhibit the retinal current I h . I h is involved in curtailing retinal responses to bright light stimuli. Under triggering circumstances (e.g., rapid changes in luminosity), partial inhibition of I h by ivabradine tablets may underlie the luminous phenomena experienced by patients. Luminous phenomena (phosphenes) are described as a transient enhanced brightness in a limited area of the visual field [see Adverse Reactions (6.1) ]. 12.2 Pharmacodynamics Ivabradine tablets causes a dose-dependent reduction in heart rate. The size of the effect is dependent on the baseline heart rate (i.e., greater heart rate reduction occurs in subjects with higher baseline heart rate). At recommended doses, heart rate reduction is approximately 10 bpm at rest and during exercise. Analysis of heart rate reduction vs. dose indicates a plateau effect at doses > 20 mg twice daily. In a study of subjects with preexisting conduction system disease (first- or second-degree AV block or left or right bundle branch block) requiring electrophysiologic study, IV ivabradine (0.20 mg/kg) administration slowed the overall heart rate by approximately 15 bpm, increased the PR interval (29 msec), and increased the AH interval (27 msec). Ivabradine tablets does not have negative inotropic effects. Ivabradine increases the uncorrected QT interval with heart rate slowing but does not cause rate-corrected prolongation of QT. 12.3 Pharmacokinetics The peak concentration (C max ) and area under the plasma concentration time curve (AUC) are similar for ivabradine and S 18982 between oral solution and tablets for the same dose. Absorption and Bioavailability Following oral administration, peak plasma ivabradine concentrations are reached in approximately1 hour under fasting conditions. The absolute oral bioavailability of ivabradine is approximately 40% because of first-pass elimination in the gut and liver. Food delays absorption by approximately 1 hour and increases plasma exposure by 20% to 40%. Ivabradine tablets should be taken with food [see Dosage and Administration (2) ]. Ivabradine is approximately 70% plasma protein bound, and the volume of distribution at steady state is approximately 100 L. Metabolism and Excretion The pharmacokinetics of ivabradine are linear over an oral dose range of 0.5 mg to 24 mg. Ivabradine is extensively metabolized in the liver and intestines by CYP3A4-mediated oxidation. The major metabolite is the N-desmethylated derivative (S 18982), which is equipotent to ivabradine and circulates at concentrations approximately 40% that of ivabradine. The N-desmethylated derivative is also metabolized by CYP3A4. Ivabradine plasma levels decline with a distribution half-life of 2 hours and an effective half-life of approximately 6 hours. The total clearance of ivabradine is 24 L/h, and renal clearance is approximately 4.2 L/h, with ~ 4% of an oral dose excreted unchanged in urine. The excretion of metabolites occurs to a similar extent via feces and urine. Drug Interactions The effects of coadministered drugs (CYP3A4 inhibitors, substrates, inducers, and other concomitantly administered drugs) on the pharmacokinetics of ivabradine tablets were studied in several single-and multiple dose studies. Pharmacokinetic measures indicating the magnitude of these interactions are presented in Figure 2. Figure 2. Impact of Coadministered Drugs on the Pharmacokinetics of Ivabradine tablets Digoxin exposure did not change when concomitantly administered with ivabradine. No dose adjustment is required when ivabradine is concomitantly administered with digoxin. Effect of Ivabradine on Metformin Pharmacokinetics Ivabradine, dosed at 10 mg twice daily to steady state, did not affect the pharmacokinetics of metformin (an organic cation transporter [OCT2] sensitive substrate). The geometric mean (90% confidence interval [CI]) ratios of C max and AUC inf of metformin, with and without ivabradine were 0.98 [0.83–1.15] and 1.02 [0.86–1.22], respectively. No dose adjustment is required for metformin when administered with ivabradine tablets. Specific Populations Age No pharmacokinetic differences (AUC or C max ) have been observed between elderly (≥ 65 years) or very elderly (≥ 75 years) patients and the overall patient population [see Use in Specific Populations (8.5) ]. Hepatic impairment In patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, the pharmacokinetics of ivabradine tablets were similar to that in patients with normal hepatic function. No data are available in patients with severe hepatic impairment (Child-Pugh C) [see Contraindications (4) ]. Renal impairment Renal impairment (creatinine clearance from 15 to 60 mL/min) has minimal effect on the pharmacokinetics of ivabradine tablets. No data are available for patients with creatinine clearance below 15 mL/min. Image"],"indications_and_usage":["1 INDICATIONS AND USAGE Ivabradine is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) 1.1 Heart Failure in Adult Patients Ivabradine tablets are indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Fetal toxicity: Females should use effective contraception. ( 5.1 ) Monitor patients for atrial fibrillation. ( 5.2 ) Monitor heart rate decreases and bradycardia symptoms during treatment. ( 5.3 ) Not recommended in patients with 2 nd degree AV block. ( 5.3 ) 5.1 Fetal Toxicity Ivabradine tablets may cause fetal toxicity when administered to a pregnant woman based on findings in animal studies. Embryo-fetal toxicity and cardiac teratogenic effects were observed in fetuses of pregnant rats treated during organogenesis at exposures 1 to 3 times the human exposures (AUC 0 - 24hr ) at the maximum recommended human dose (MRHD) [see Use in Specific Populations (8.1) ]. Advise females of reproductive potential to use effective contraception when taking ivabradine tablets [see Use in Specific Populations (8.3) ] . 5.2 Atrial Fibrillation Ivabradine tablets increases the risk of atrial fibrillation. In the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT), the rate of atrial fibrillation was 5.0% per patient-year in patients treated with ivabradine tablets and 3.9% per patient-year in patients treated with placebo [see Clinical Studies (14) ] . Regularly monitor cardiac rhythm. Discontinue ivabradine tablets if atrial fibrillation develops. 5.3 Bradycardia and Conduction Disturbances Adult Patients Bradycardia, sinus arrest, and heart block have occurred with ivabradine tablets. The rate of bradycardia was 6.0% per patient-year in patients treated with ivabradine tablets (2.7% symptomatic; 3.4% asymptomatic) and 1.3% per patient-year in patients treated with placebo. Risk factors for bradycardia include sinus node dysfunction, conduction defects (e.g., 1 st or 2 nd degree atrioventricular block, bundle branch block), ventricular dyssynchrony, and use of other negative chronotropes (e.g., digoxin, diltiazem, verapamil, amiodarone). Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions (6.2) ] . Concurrent use of verapamil or diltiazem will increase ivabradine tablets exposure, may themselves contribute to heart rate lowering, and should be avoided [see Clinical Pharmacology (12.3) ] . Avoid use of ivabradine tablets in patients with 2 nd degree atrioventricular block unless a functioning demand pacemaker is present [see Contraindications (4) ]."],"clinical_studies_table":["
Table 3. SHIFT – Incidence of the Primary Composite Endpoint and Components
aPatients who died on the same calendar day as their first hospitalization for worsening heart
failure are counted under cardiovascular death.
bAnalyses of the components of the primary composite endpoint were not prospectively planned to be adjusted for multiplicity.
N: number of patients at risk; n: number of patients having experienced the endpoint; %: incidence rate = (n/N) × 100; % PY: annual incidence rate = (n/number of patient-years) × 100; CI:Confidence interval
Endpoint Ivabradine tablets (N = 3,241) % Placebo (N = 3,264) % Hazard
n % PY n % PY Ratio [95%CI] p-value
Primary composite endpoint: 793 24.5 14.5 937 28.7 17.7 0.82 [0.75 , 0.90] < 0.0001
Time to first hospitalization for worsening heart failure or cardiovascular death a 505 15.6 9.2 660 20.2 12.5
Hospitalization for worsening heart failure Cardiovascular death as first event 288 8.9 4.8 277 8.5 4.7
Subjects with events at any Time Hospitalization for worsening heart failure b 514 15.9 9.4 672 20.6 12.7 0.74 [0.66 , 0.83]
Cardiovascular death b 449 13.9 7.5 491 15.0 8.3 0.91 [0.80 , 1.03]
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of carcinogenicity when mice and rats received ivabradine up to 104 weeks by dietary administration. High doses in these studies were associated with mean ivabradine exposures of at least 37 times higher than the human exposure (AUC 0-24hr ) at the MRHD. Ivabradine tested negative in the following assays: bacterial reverse mutation (Ames) assay, in vivo bone marrow micronucleus assay in both mouse and rat, in vivo chromosomal aberration assay in rats, and in vivo unscheduled DNA synthesis assay in rats. Results of the in vitro chromosomal aberration assay were equivocal at concentrations approximately 1,500 times the human C max at the MRHD. Ivabradine tested positive in the mouse lymphoma assays and in vitro unscheduled DNA synthesis assay in rat hepatocytes at concentrations greater than 1,500 times the human C max at the MRHD. Reproduction toxicity studies in animals demonstrated that ivabradine did not affect fertility in male or female rats at exposures 46 to 133 times the human exposure (AUC 0-24hr ) at the MRHD. 13.2 Animal Toxicology and/or Pharmacology Reversible changes in retinal function were observed in dogs administered oral ivabradine at total doses of 2, 7, or 24 mg/kg/day (approximately 0.6 to 50 times the human exposure at the MRHD based on AUC 0-24hr ) for 52 weeks. Retinal function assessed by electroretinography demonstrated reductions in cone system responses, which reversed within a week post-dosing, and were not associated with damage to ocular structures as evaluated by light microscopy. These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarization-activated I h currents in the retina, which share homology with the cardiac pacemaker I f current."],"adverse_reactions_table":["
Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher on Ivabradine than Placebo occurring in > 1% on Ivabradine in SHIFT
Ivabradine N = 3,260 Placebo N = 3,278
Bradycardia 10 % 2.2 %
Hypertension, Blood Pressure Increased 8.9 % 7.8 %
Atrial fibrillation 8.3 % 6.6 %
Phosphenes, visual brightness 2.8 % 0.5 %
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labelling [see Medication Guide and Instructions for Use] . ● Fetal Toxicity Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception and to notify their healthcare provider with a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1) , (8.3) ]. ● Low Heart Rate Advise patients to report significant decreases in heart rate or symptoms such as dizziness, fatigue, or hypotension [see Warnings and Precautions (5.3) ] . ● Atrial Fibrillation Advise patients to report symptoms of atrial fibrillation, such as heart palpitations or racing, chest pressure, or worsened shortness of breath [see Warnings and Precautions (5.2) ] . ● Phosphenes Advise patients about the possible occurrence of luminous phenomena (phosphenes). Advise patients to use caution if they are driving or using machines in situations where sudden changes in light intensity may occur, especially when driving at night. Advise patients that phosphenes may subside spontaneously during continued treatment with ivabradine tablets [see Adverse Reactions (6.1) ] . ● Drug Interactions Advise patients to avoid ingestion of grapefruit juice and St. John's wort [see Drug Interactions (7.1) ]. ● Intake with Food Advise patients to take ivabradine tablets twice daily with food [see Dosage and Administration (2) ] . Manufactured for: Ingenus Pharmaceuticals, LLC Orlando, FL 32811-7193 Made in India Dispense with Medication Guide available at: www.ingenus.com/medguide/ivabradine-tablets.pdf Marketed by: GSMS, Inc. Camarillo, CA 93012 USA Image"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Adult patients ● Starting dose is 2.5 (vulnerable adults) or 5 mg twice daily with food. After 2 weeks of treatment, adjust dose based on heart rate. The maximum dose is 7.5 mg twice daily. ( 2.1 ) 2.1 Adults The recommended starting dose of ivabradine tablets is 5 mg twice daily with food. Assess patient after two weeks and adjust dose to achieve a resting heart rate between 50 and 60 beats per minute (bpm) as shown in Table 1. Thereafter, adjust dose as needed based on resting heart rate and tolerability. The maximum dose is 7.5 mg twice daily. In adult patients unable to swallow tablets, Corlanor oral solution can be used [see Clinical Pharmacology (12.3) ] . In patients with a history of conduction defects or other patients in whom bradycardia could lead to hemodynamic compromise, initiate therapy at 2.5 mg twice daily before increasing the dose based on heart rate [see Warnings and Precautions (5.3) ] . Table 1. Dose Adjustment for Adults * [see Warnings and Precautions (5.3) ] Heart Rate Dose Adjustment > 60 bpm Increase dose by 2.5 mg (given twice daily) up to a maximum dose of 7.5 mg twice daily 50-60 bpm Maintain dose < 50 bpm or signs and symptoms of bradycardia Decrease dose by 2.5 mg (given twice daily); if current dose is 2.5 mg twice daily, discontinue therapy*"],"spl_product_data_elements":["IVABRADINE IVABRADINE LACTOSE MONOHYDRATE MALTODEXTRIN STARCH, CORN SILICON DIOXIDE MAGNESIUM STEARATE TITANIUM DIOXIDE HYPROMELLOSE 2910 (15 MPA.S) POLYETHYLENE GLYCOL 4000 FERRIC OXIDE YELLOW FERRIC OXIDE RED IVABRADINE HYDROCHLORIDE IVABRADINE Light salmon-colored I;5 IVABRADINE IVABRADINE LACTOSE MONOHYDRATE MALTODEXTRIN STARCH, CORN SILICON DIOXIDE MAGNESIUM STEARATE TITANIUM DIOXIDE HYPROMELLOSE 2910 (15 MPA.S) POLYETHYLENE GLYCOL 4000 FERRIC OXIDE YELLOW FERRIC OXIDE RED IVABRADINE HYDROCHLORIDE IVABRADINE Light salmon-colored I;7;5"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Tablets Ivabradine tablets 5 mg: Light salmon-colored, capsule-shaped, film-coated scored tablet debossed with \"I5\" divided by score on one side and plain on other side. The tablet is scored and can be divided into equal halves to provide a 2.5 mg dose. Ivabradine tablets 7.5 mg: Light salmon-colored, round-shaped, film-coated tablet debossed with \"I\" on one side & 7.5 on other side. Tablets: 5 mg, 7.5 mg ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Breastfeeding not recommended. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings in animals, ivabradine tablets may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies of ivabradine tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies, oral administration of ivabradine to pregnant rats during organogenesis at a dosage providing 1 to 3 times the human exposure (AUC 0-24hr ) at the MRHD resulted in embryo-fetal toxicity and teratogenicity manifested as abnormal shape of the heart, interventricular septal defect, and complex anomalies of primary arteries. Increased post-natal mortality was associated with these teratogenic effects in rats. In pregnant rabbits, increased post-implantation loss was noted at an exposure (AUC 0-24hr ) 5 times the human exposure at the MRHD. Lower doses were not tested in rabbits. The background risk of major birth defects for the indicated population is unknown. The estimated background risk of major birth defects in the U.S. general population is 2 to 4%, however, and the estimated risk of miscarriage is 15 to 20% in clinically recognized pregnancies. Advise a pregnant woman of the potential risk to the fetus. Clinical Considerations Disease-associated Maternal and/or Embryo-fetal Risk Stroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester. Pregnant patients with left ventricular ejection fraction less than 35% on maximally tolerated doses of beta-blockers may be particularly heart rate dependent for augmenting cardiac output. Therefore, pregnant patients who are started on ivabradine tablets, especially during the first trimester, should be followed closely for destabilization of their congestive heart failure that could result from heart rate slowing. Monitor pregnant women with chronic heart failure in 3 rd trimester of pregnancy for preterm birth. Data Animal Data In pregnant rats, oral administration of ivabradine during the period of organogenesis (gestation day 6-15) at doses of 2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and teratogenic effects. Increased intrauterine and post-natal mortality and cardiac malformations were observed at doses ≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0-24hr ). Teratogenic effects including interventricular septal defect and complex anomalies of major arteries were observed at doses ≥ 4.6mg/kg/day (approximately 3 times the human exposure at the MRHD based on AUC 0-24hr ). In pregnant rabbits, oral administration of ivabradine during the period of organogenesis (gestation day 6-18) at doses of 7, 14, or 28 mg/kg/day resulted in fetal toxicity and teratogenicity. Treatment with all doses ≥ 7 mg/kg/day (equivalent to the human exposure at the MRHD based on AUC 0-24hr ) caused an increase in post-implantation loss. At the high dose of 28 mg/kg/day (approximately 15 times the human exposure at the MRHD based on AUC 0-24hr ), reduced fetal and placental weights were observed, and evidence of teratogenicity (ectrodactylia observed in 2 of 148 fetuses from 2 of 18 litters) was demonstrated. In the pre- and post-natal study, pregnant rats received oral administration of ivabradine at doses of 2.5, 7, or 20 mg/kg/day from gestation day 6 to lactation day 20. Increased post-natal mortality associated with cardiac teratogenic findings was observed in the F1 pups delivered by dams treated at the high dose (approximately 15 times the human exposure at the MRHD based on AUC 0-24hr ). 8.2 Lactation Risk Summary There is no information regarding the presence of ivabradine in human milk, the effects of ivabradine on the breastfed infant, or the effects of the drug on milk production. Animal studies have shown, however, that ivabradine is present in rat milk [see Data]. Because of the potential risk to breastfed infants from exposure to ivabradine tablets, breastfeeding is not recommended. Data Lactating rats received daily oral doses of [14C]-ivabradine (7 mg/kg) on post-parturition days 10 to 14; milk and maternal plasma were collected at 0.5 and 2.5 hours post-dose on day 14. The ratios of total radio activity associated with [14C]-ivabradine or its metabolites in milk vs. plasma were 1.5 and 1.8, respectively, indicating that ivabradine is transferred to milk after oral administration. 8.3 Females and Males of Reproductive Potential Contraception Females Ivabradine tablets may cause fetal harm, based on animal data. Advise females of reproductive potential to use effective contraception during ivabradine tablets treatment [see Use in Specific Populations (8.1) ]. 8.4 Pediatric Use The safety and efficacy of ivabradine tablets have not been established in patients less than 6 months of age. 8.5 Geriatric Use No pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population. However, ivabradine tablets has only been studied in a limited number of patients ≥ 75 years of age. 8.6 Hepatic Impairment No dose adjustment is required in patients with mild or moderate hepatic impairment. Ivabradine tablets is contraindicated in patients with severe hepatic impairment (Child-Pugh C) as it has not been studied in this population and an increase in systemic exposure is anticipated [see Contraindications (4) and Clinical Pharmacology (12.3) ]. 8.7 Renal Impairment No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min. No data are available for patients with creatinine clearance below 15 mL/min [see Clinical Pharmacology (12.3) ]."],"dosage_and_administration_table":["
Table 1. Dose Adjustment for Adults
* [see Warnings and Precautions (5.3)]
Heart Rate Dose Adjustment
> 60 bpm Increase dose by 2.5 mg (given twice daily) up to a maximum dose of 7.5 mg twice daily
50-60 bpm Maintain dose
< 50 bpm or signs and symptoms of bradycardia Decrease dose by 2.5 mg (given twice daily); if current dose is 2.5 mg twice daily, discontinue therapy*
"],"animal_pharmacology_and_or_toxicology":["13.2 Animal Toxicology and/or Pharmacology Reversible changes in retinal function were observed in dogs administered oral ivabradine at total doses of 2, 7, or 24 mg/kg/day (approximately 0.6 to 50 times the human exposure at the MRHD based on AUC 0-24hr ) for 52 weeks. Retinal function assessed by electroretinography demonstrated reductions in cone system responses, which reversed within a week post-dosing, and were not associated with damage to ocular structures as evaluated by light microscopy. These data are consistent with the pharmacological effect of ivabradine related to its interaction with hyperpolarization-activated I h currents in the retina, which share homology with the cardiac pacemaker I f current."],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 51407-592-60OL .jpg 51407-593-60OL.jpg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility There was no evidence of carcinogenicity when mice and rats received ivabradine up to 104 weeks by dietary administration. High doses in these studies were associated with mean ivabradine exposures of at least 37 times higher than the human exposure (AUC 0-24hr ) at the MRHD. Ivabradine tested negative in the following assays: bacterial reverse mutation (Ames) assay, in vivo bone marrow micronucleus assay in both mouse and rat, in vivo chromosomal aberration assay in rats, and in vivo unscheduled DNA synthesis assay in rats. Results of the in vitro chromosomal aberration assay were equivocal at concentrations approximately 1,500 times the human C max at the MRHD. Ivabradine tested positive in the mouse lymphoma assays and in vitro unscheduled DNA synthesis assay in rat hepatocytes at concentrations greater than 1,500 times the human C max at the MRHD. Reproduction toxicity studies in animals demonstrated that ivabradine did not affect fertility in male or female rats at exposures 46 to 133 times the human exposure (AUC 0-24hr ) at the MRHD."]},"tags":[{"label":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","category":"target"},{"label":"HCN1","category":"gene"},{"label":"HCN3","category":"gene"},{"label":"HCN4","category":"gene"},{"label":"C01EB17","category":"atc"},{"label":"Oral","category":"route"},{"label":"Solution","category":"form"},{"label":"Tablet","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Angina pectoris","category":"indication"},{"label":"Chronic heart failure","category":"indication"},{"label":"Amgen Inc","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1295 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"460 reports"},{"date":"","signal":"HYPOTENSION","source":"FDA FAERS","actionTaken":"413 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"350 reports"},{"date":"","signal":"CARDIAC FAILURE","source":"FDA FAERS","actionTaken":"324 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"317 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"308 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"270 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"253 reports"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"248 reports"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"}],"commonSideEffects":[{"effect":"Bradycardia","drugRate":"10%","severity":"common","_validated":true},{"effect":"Hypertension","drugRate":"8.9%","severity":"common","_validated":true},{"effect":"Atrial fibrillation","drugRate":"8.3%","severity":"common","_validated":true},{"effect":"Phosphenes","drugRate":"2.8%","severity":"mild","_validated":true},{"effect":"Syncope","drugRate":"reported","severity":"unknown"},{"effect":"Hypotension","drugRate":"reported","severity":"unknown"},{"effect":"Torsade de pointes","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular fibrillation","drugRate":"reported","severity":"unknown"},{"effect":"Ventricular tachycardia","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Erythema","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Vertigo","drugRate":"reported","severity":"unknown"},{"effect":"Diplopia","drugRate":"reported","severity":"unknown"},{"effect":"Visual impairment","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"Based on findings in animals, Corlanor may cause fetal harm when administered to pregnant woman. There are no adequate and well-controlled studies of Corlanor in pregnant women to inform any drug-associated risks. In animal reproduction studies, oral administration of ivabradine to pregnant rats during organogenesis at dosage providing to times the human exposure (AUC 0-24hr) at the MRHD resulted in embryo-fetal toxicity and teratogenicity manifested as abnormal shape of the heart, interventricular septal defect, and complex anomalies of primary arteries. Increased post-natal mortality was associated with these teratogenic effects in rats. In pregnant rabbits, increased post-implantation loss was noted at an exposure (AUC 0-24hr) times the human exposure at the MRHD. Lower doses were not tested in rabbits. The background risk of major birth defects for the indicated population is unknown. The estimated background risk of major birth defects in the U.S. general population is to 4%, however, and the estimated risk of miscarriage is 15 to 20% in clinically recognized pregnancies. Advise pregnant woman of the potential risk to the fetus. Clinical Considerations. Disease-associated Maternal and/or Embryo-fetal RiskStroke volume and heart rate increase during pregnancy, increasing cardiac output, especially during the first trimester","Geriatric use":"No pharmacokinetic differences have been observed in elderly (>= 65 years) or very elderly (>= 75 years) patients compared to the overall population. However, Corlanor has only been studied in limited number of patients >= 75 years of age.","Paediatric use":"The safety and effectiveness of Corlanor have been established in pediatric patients (age months to less than 18 years old) and are supported by pharmacokinetic and pharmacodynamic trials and evidence from adequate and well-controlled trials of Corlanor in adult patients. The pediatric study included 116 patients in the following age groups: 17 patients in the months to less than 12 months age group, 36 patients in the year to less than years age group, and 63 patients in the "}},"trials":[],"aliases":[],"company":"Amgen","patents":[{"applNo":"N209964","source":"FDA Orange Book","status":"Active","expires":"Dec 12, 2026","useCode":"U-1694","territory":"US","drugProduct":true,"patentNumber":"7867996","drugSubstance":true},{"applNo":"N209964","source":"FDA Orange Book","status":"Active","expires":"Feb 22, 2026","useCode":"U-1694","territory":"US","drugProduct":true,"patentNumber":"7361650","drugSubstance":true},{"applNo":"N209964","source":"FDA Orange Book","status":"Active","expires":"Feb 22, 2026","useCode":"U-1694","territory":"US","drugProduct":true,"patentNumber":"7361649","drugSubstance":true},{"applNo":"N209964","source":"FDA Orange Book","status":"Active","expires":"Feb 22, 2026","useCode":"U-1694","territory":"US","drugProduct":true,"patentNumber":"7879842","drugSubstance":true}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-10-23","unitCost":"$4.5638/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,666","description":"IVABRADINE HCL 5 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IVABRADINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:11:59.945651+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:11:59.945557+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Ivabradine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:12:06.997635+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:12:05.505971+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T01:12:00.017691+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:11:58.769147+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IVABRADINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:12:05.936585+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:57.632910+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:57.632948+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:12:07.422585+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:06.997570+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL471737/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:12:06.645059+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA214051","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:11:57.632952+00:00"}},"allNames":"corlanor","offLabel":[],"synonyms":["corlanor","corlentor","ivabradine hydrochloride","ivabradine","coraxan","procoralan","ivabradine HCl"],"timeline":[{"date":"2005-10-25","type":"positive","source":"DrugCentral","milestone":"EMA approval (Les Laboratoires Servier)"},{"date":"2015-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from AMGEN INC to Amgen Inc"},{"date":"2015-04-15","type":"positive","source":"DrugCentral","milestone":"FDA approval (Amgen Inc)"},{"date":"2019-09-20","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Ono Pharmaceutical Co., Ltd.)"},{"date":"2026-02-22","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7361650 expires"},{"date":"2026-04-22","type":"negative","source":"FDA Orange Book","milestone":"ODE-234 exclusivity expires"},{"date":"2026-10-22","type":"negative","source":"FDA Orange Book","milestone":"Pediatric exclusivity expires"},{"date":"2026-12-12","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 7867996 expires"}],"aiSummary":"Corlanor (Ivabradine) is a small molecule hyperpolarization-activated cyclic nucleotide-gated channel blocker developed by Amgen Inc. It targets the potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 to treat angina pectoris and chronic heart failure. Corlanor is a patented medication with no generic manufacturers available. Key safety considerations include bradycardia and worsening heart failure in certain patients. It was FDA-approved in 2015.","approvals":[{"date":"2005-10-25","orphan":false,"company":"Les Laboratoires Servier","regulator":"EMA"},{"date":"2015-04-15","orphan":false,"company":"AMGEN INC","regulator":"FDA"},{"date":"2019-09-20","orphan":false,"company":"Ono Pharmaceutical Co., Ltd.","regulator":"PMDA"}],"brandName":"Corlanor","ecosystem":[{"indication":"Angina pectoris","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atenolol","slug":"atenolol","company":"Alvogen Ipco Sarl"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"bepridil","slug":"bepridil","company":""}],"globalPrevalence":112000000},{"indication":"Chronic heart failure","otherDrugs":[{"name":"candesartan cilexetil","slug":"candesartan-cilexetil","company":"Astrazeneca"},{"name":"captopril","slug":"captopril","company":"Par Pharm"},{"name":"carvedilol","slug":"carvedilol","company":"Smithkline Beecham"},{"name":"chlorothiazide","slug":"chlorothiazide","company":"Oak Pharms Akorn"}],"globalPrevalence":64000000}],"mechanism":{"target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","novelty":"Follow-on","targets":[{"gene":"HCN1","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1"},{"gene":"HCN3","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3"},{"gene":"HCN4","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4"},{"gene":"HCN2","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2"}],"moaClass":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists","modality":"Small Molecule","drugClass":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker","explanation":"","oneSentence":"","technicalDetail":"Corlanor specifically targets the If channel, a hyperpolarization-activated cyclic nucleotide-gated channel, to inhibit the funny current (If) and thereby reduce the heart rate."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Ivabradine","title":"Ivabradine","extract":"Ivabradine, sold under the brand name Procoralan among others, is a medication, which is a pacemaker current (If) inhibitor, used for the symptomatic management of heart-related chest pain and heart failure. Patients who qualify for use of ivabradine for congestive heart failure are patients who have symptomatic heart failure, with reduced ejection fraction, and heart rate at least 70 bpm, and the condition not able to be fully managed by beta blockers.","wiki_society_and_culture":"==Society and culture==\n\n===Approval===\nIvabradine was approved by the European Medicines Agency in 2005, and by the United States Food and Drug Administration in 2015.\n\n===Alleged conflict of interest===\nAccording to a documentary and article of the Danish media channel TV2 in September 2024, a former president of the European Society of Cardiology during 2006-2008, professor Kim Fox, had a conflict of interest in relation to clinical trials of ivabradine and his recommendation of ivabradine based on the trials. According to TV2, Fox and his partner founded a company, Heart Research Ltd., which performed clinical trials and received payments from the pharmaceutical industry, allowing them to extract a total profit of 500 million DKK (67 million euro) during 2003-2015, mostly from a cooperation with the French pharmaceutical company Servier. According to TV2's research of financial statements of the company, in the period of 2004-2006, the couple received a salary of over 20 million DKK (2.7 million euro) from their company, while during the same period, Kim Fox was chairman of the taskforce recommending ivabradine, and as president of the European Society of Cardiology, he also had the role of presenting the research results and recommending ivabradin as a \"gold standard\" treatment at a European cardiological conference in 2008. Karsten Juhl Jørgensen, professor of medicine and conflict of interests expert at Odense University and the Nordic Cochrane Centre, commented that the conflict of interest was \"probably the largest he had seen\". Danish chief physician Niels Holmark Andersen commented that Fox's conflict of interest was of an \"oligarchal magnitude\" and \"the mother of all conflicts of interests\" because Fox was involved in all parts of the process, that the clinical results did not sustain claims of the superiority of the medication which has serious adverse effect, and further that Servier had marketed ivabradine \"aggressively\" and offered physicians exclusi"},"commercial":{"launchDate":"2015","_launchSource":"DrugCentral (FDA 2015-04-15, AMGEN INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3312","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IVABRADINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IVABRADINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Ivabradine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T14:01:57.800325","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:09.955877+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"camphor","drugSlug":"camphor","fdaApproval":"","relationship":"same-class"},{"drugName":"indomethacin","drugSlug":"indomethacin","fdaApproval":"1965-06-10","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ubidecarenone","drugSlug":"ubidecarenone","fdaApproval":"","relationship":"same-class"},{"drugName":"adenosine","drugSlug":"adenosine","fdaApproval":"1989-10-30","genericCount":15,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ibuprofen","drugSlug":"ibuprofen","fdaApproval":"1974-09-19","patentExpiry":"Sep 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ranolazine","drugSlug":"ranolazine","fdaApproval":"2006-01-27","patentExpiry":"Jan 24, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"regadenoson","drugSlug":"regadenoson","fdaApproval":"2008-04-10","patentExpiry":"Feb 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"mavacamten","drugSlug":"mavacamten","fdaApproval":"2022-04-28","patentExpiry":"Jun 19, 2034","patentStatus":"Patent protected","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"exclusivity":[{"code":"ODE-234","date":"Apr 22, 2026"},{"code":"PED","date":"Oct 22, 2026"}],"genericName":"ivabradine","indications":{"approved":[{"name":"Angina pectoris","source":"DrugCentral","snomedId":194828000,"regulator":"FDA","eligibility":null,"usPrevalence":null,"globalPrevalence":112000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Chronic heart failure","source":"DrugCentral","snomedId":48447003,"regulator":"FDA","eligibility":{"Adult Patients":{"age":null,"heart rate":">= 70 beats per minute","sinus rhythm":true,"beta-blocker use":"maximally tolerated doses or contraindication","left ventricular ejection fraction":"<= 35%"},"Pediatric Patients":{"age":">= 6 months","heart rate":"elevated","sinus rhythm":true,"dilated cardiomyopathy":true}},"usPrevalence":6200000,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"ESC Heart Failure, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Amgen Inc","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"camphor","brandName":"camphor","genericName":"camphor","approvalYear":"","relationship":"same-class"},{"drugId":"indomethacin","brandName":"indomethacin","genericName":"indomethacin","approvalYear":"1965","relationship":"same-class"},{"drugId":"ubidecarenone","brandName":"ubidecarenone","genericName":"ubidecarenone","approvalYear":"","relationship":"same-class"},{"drugId":"adenosine","brandName":"adenosine","genericName":"adenosine","approvalYear":"1989","relationship":"same-class"},{"drugId":"ibuprofen","brandName":"ibuprofen","genericName":"ibuprofen","approvalYear":"1974","relationship":"same-class"},{"drugId":"ranolazine","brandName":"ranolazine","genericName":"ranolazine","approvalYear":"2006","relationship":"same-class"},{"drugId":"regadenoson","brandName":"regadenoson","genericName":"regadenoson","approvalYear":"2008","relationship":"same-class"},{"drugId":"mavacamten","brandName":"mavacamten","genericName":"mavacamten","approvalYear":"2022","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04031573","phase":"PHASE3","title":"Ivabradine for Heart Rate Control In Septic Shock","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-02-26","conditions":["Septic Shock"],"enrollment":429,"completionDate":"2026-04-22"},{"nctId":"NCT05081999","phase":"PHASE4","title":"De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alberta","startDate":"2023-01-30","conditions":["Stable Ischemic Heart Disease","Coronary Artery Disease","Beta-blocker Therapy"],"enrollment":59,"completionDate":"2026-12-31"},{"nctId":"NCT06305780","phase":"PHASE2","title":"RECOVER-AUTONOMIC Platform Protocol","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":["Long COVID","Long Covid19","Long Covid-19"],"enrollment":381,"completionDate":"2025-07-09"},{"nctId":"NCT06305806","phase":"PHASE2","title":"RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)","status":"COMPLETED","sponsor":"Kanecia Obie Zimmerman","startDate":"2024-03-11","conditions":["Long COVID","Long Covid19","Long Covid-19"],"enrollment":181,"completionDate":"2025-12-17"},{"nctId":"NCT02584439","phase":"PHASE3","title":"Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2015-12-03","conditions":["Healthy","Vascular Stiffness","Aging"],"enrollment":20,"completionDate":"2019-07-15"},{"nctId":"NCT04853797","phase":"NA","title":"Effect of Ivabradine on Levcromakalim-Induced Symptoms in Individuals With Migraine Without Aura (ILIM)","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2021-05-11","conditions":["Headache","Migraine Without Aura"],"enrollment":37,"completionDate":"2025-07-06"},{"nctId":"NCT07268170","phase":"PHASE2,PHASE3","title":"Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Gødstrup Hospital","startDate":"2025-12-15","conditions":["Coronary Arterial Disease (CAD)","Ischemic Heart Disease (IHD)"],"enrollment":350,"completionDate":"2028-09-30"},{"nctId":"NCT05279651","phase":"PHASE3","title":"Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jagiellonian University","startDate":"2022-06-13","conditions":["Myocardial Injury After Noncardiac Surgery (MINS)","Myocardial Ischemia"],"enrollment":2146,"completionDate":"2026-06-30"},{"nctId":"NCT07135258","phase":"PHASE4","title":"Atrial Fibrillation: In Search for the Optimal Target for Rate Control","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-10-01","conditions":["Atrial Fibrillation (Permanent)","Atrial Fibrillation (AF)"],"enrollment":200,"completionDate":"2027-10-01"},{"nctId":"NCT05636774","phase":"NA","title":"Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2022-12-12","conditions":["Patients With Advanced Cancer Receiving Specialized Palliative Care"],"enrollment":97,"completionDate":"2025-03-01"},{"nctId":"NCT03168529","phase":"PHASE4","title":"Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit","status":"TERMINATED","sponsor":"Phillip Levy","startDate":"2018-07-01","conditions":["Heart Failure"],"enrollment":19,"completionDate":"2021-12-31"},{"nctId":"NCT05572957","phase":"NA","title":"LBBP as Initial Therapy in Patients With Non-ischemic Heart Failure and LBBB","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-10-14","conditions":["Non-ischemic Cardiomyopathy","Heart Failure","Left Bundle-Branch Block"],"enrollment":50,"completionDate":"2026-12"},{"nctId":"NCT06742164","phase":"NA","title":"Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-12-30","conditions":["Heart Rhythm Disorder"],"enrollment":76,"completionDate":"2025-06-30"},{"nctId":"NCT03631654","phase":"PHASE4","title":"Ivabradine in Stage D Heart Failure Patients on Chronic Inotropes","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2020-10-01","conditions":["Heart Failure NYHA Class IV"],"enrollment":0,"completionDate":"2021-08-31"},{"nctId":"NCT06670690","phase":"NA","title":"Comparison Between Atenolol,Propnalol and Ivabradine","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2023-09-01","conditions":["Intraoperative Bleeding"],"enrollment":120,"completionDate":"2023-10-01"},{"nctId":"NCT04285736","phase":"PHASE2,PHASE3","title":"Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI","status":"COMPLETED","sponsor":"Cairo University","startDate":"2014-12","conditions":["NSTEMI"],"enrollment":100,"completionDate":"2016-05"},{"nctId":"NCT02446990","phase":"PHASE3","title":"Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2009-09","conditions":["Coronary Artery Disease"],"enrollment":19102,"completionDate":"2014-01"},{"nctId":"NCT00202579","phase":"PHASE2","title":"Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2004-09","conditions":["Heart Failure, Congestive"],"enrollment":12,"completionDate":"2006-02"},{"nctId":"NCT06505668","phase":"NA","title":"Effect of Atenolol Versus Ivabradine on HRV in TRS Patients on Clozapine With Tachycardia: A Randomised Control Trial.","status":"RECRUITING","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2023-08-01","conditions":["Treatment Resistant Schizophrenia","Clozapine Adverse Reaction","Heart Rate Variability","Tachycardia"],"enrollment":40,"completionDate":"2025-06-30"},{"nctId":"NCT04186286","phase":"PHASE2","title":"Crossover Study of Propranolol vs Ivabradine in POTS","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2021-02-01","conditions":["Postural Tachycardia Syndrome"],"enrollment":20,"completionDate":"2026-12-31"},{"nctId":"NCT04881318","phase":"NA","title":"Compression Garments in the Community With POTS","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2021-05-17","conditions":["Postural Orthostatic Tachycardia Syndrome"],"enrollment":30,"completionDate":"2024-12-31"},{"nctId":"NCT06371222","phase":"PHASE4","title":"Role of Ivabradine on Heart Rate and Quality of Life in Patients With Mitral Stenosis in Sinus Rhythm","status":"COMPLETED","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-02-01","conditions":["Mitral Stenosis"],"enrollment":42,"completionDate":"2024-02-01"},{"nctId":"NCT06312891","phase":"","title":"Value of Heart Rate Lowering Therapy in Acute Myocarditis","status":"RECRUITING","sponsor":"Assiut University","startDate":"2024-04-01","conditions":["Myocarditis"],"enrollment":150,"completionDate":"2025-06-01"},{"nctId":"NCT04111133","phase":"NA","title":"Ivabradine in Cirrhotic Cardiomyopathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-01-01","conditions":["Cirrhotic Cardiomyopathy","Left Ventricular Dysfunction","Cirrhosis, Liver","Portal Hypertension"],"enrollment":130,"completionDate":"2024-12"},{"nctId":"NCT05882708","phase":"PHASE4","title":"Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2023-06-01","conditions":["Sepsis","Ivabradine","Hemodynamics","Heart Rate Control"],"enrollment":172,"completionDate":"2025-03-31"},{"nctId":"NCT02973594","phase":"PHASE4","title":"Pulse Reduction On Beta-blocker and Ivabradine Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2016-11","conditions":["Dilated Cardiomyopathies, Idiopathic","Heart Failure, Systolic","Ventricular Remodeling","Electrical Remodeling"],"enrollment":28,"completionDate":"2023-06-30"},{"nctId":"NCT05481177","phase":"PHASE4","title":"Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort","status":"UNKNOWN","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2023-06-14","conditions":["Long Haul COVID","Postural Orthostatic Tachycardia Syndrome"],"enrollment":250,"completionDate":"2024-09-01"},{"nctId":"NCT05973591","phase":"","title":"The Impact of Ivabradine on Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy (NIDCM) on Current Medical Therapy Era","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2023-07-15","conditions":["Dilated Cardiomyopathy","Ventricular Remodeling","Heart Failure, Reduced Ejection Fraction"],"enrollment":500,"completionDate":"2024-12-31"},{"nctId":"NCT02592499","phase":"NA","title":"Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2016-06","conditions":["End-stage Heart Failure"],"enrollment":80,"completionDate":"2025-12"},{"nctId":"NCT05580510","phase":"PHASE2,PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":["Congenital Heart Disease","Heart Failure","Heart Failure With Reduced Ejection Fraction"],"enrollment":160,"completionDate":"2024-03-29"},{"nctId":"NCT05594342","phase":"PHASE3","title":"Ivabradine Effects in Cardiogenic Shock Requiring Inotropic Support","status":"UNKNOWN","sponsor":"The Young Investigator Group of Cardiovascular Research","startDate":"2022-07-01","conditions":["Heart Failure","Cardiogenic Shock","Ischemic Heart Disease"],"enrollment":200,"completionDate":"2023-01-01"},{"nctId":"NCT03718273","phase":"PHASE3","title":"IvaBRAdine blocK of Funny Current for Heart Rate Control in permanEnt Atrial Fibrillation. (BRAKE-AF Study).","status":"COMPLETED","sponsor":"Adolfo Fontenla","startDate":"2018-10-19","conditions":["Atrial Fibrillation","Heart Diseases"],"enrollment":68,"completionDate":"2022-06-30"},{"nctId":"NCT05141071","phase":"PHASE2","title":"Effect of Ivabradine on Microcirculation and Cardiac Output in Septic Shock Patients","status":"COMPLETED","sponsor":"Cairo University","startDate":"2021-11-25","conditions":["Septic Shock"],"enrollment":44,"completionDate":"2022-06-05"},{"nctId":"NCT05261464","phase":"PHASE4","title":"Heart Rate Controller in Computed Tomography Coronary Angiography","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-01-30","conditions":["Heart Rate","Coronary Computed Tomography Angiography"],"enrollment":246,"completionDate":"2022-06-30"},{"nctId":"NCT05348057","phase":"PHASE4","title":"Clinical Study of CMR to Evaluate the Effect of Ivabradine on the Improvement of Left Ventricular Remodeling in STEMI Patients After Primary PCI","status":"UNKNOWN","sponsor":"Qian geng","startDate":"2021-08-01","conditions":["Cardiovascular Diseases"],"enrollment":240,"completionDate":"2022-09-01"},{"nctId":"NCT04436016","phase":"PHASE4","title":"PeRiOperaTivE CardioproTection With Ivabradine in Non-cardiac Surgery","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2020-10-05","conditions":["Myocardial Injury","Myocardial Ischemia"],"enrollment":78,"completionDate":"2022-01-11"},{"nctId":"NCT03137537","phase":"PHASE2","title":"Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-02-27","conditions":["Lymphoma","Autonomic Imbalance","Cancer Survivorship"],"enrollment":23,"completionDate":"2020-11-18"},{"nctId":"NCT04217135","phase":"PHASE4","title":"The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation","status":"UNKNOWN","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2017-01-01","conditions":["Systolic Heart Failure Stage D (Disorder)","Mitral Regurgitation"],"enrollment":400,"completionDate":"2022-07-31"},{"nctId":"NCT05168189","phase":"","title":"the Role of Ivabradine in Causing AF in Patients With Chronic Coronary Syndrome","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-08","conditions":["AF - Atrial Fibrillation"],"enrollment":180,"completionDate":"2024-01"},{"nctId":"NCT03456856","phase":"PHASE4","title":"A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-09-28","conditions":["Heart Failure (HF)"],"enrollment":30,"completionDate":"2019-05-20"},{"nctId":"NCT04448899","phase":"PHASE4","title":"Ivabradine in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2020-06-01","conditions":["Congestive Heart Failure"],"enrollment":60,"completionDate":"2021-02-05"},{"nctId":"NCT03987204","phase":"PHASE1","title":"Ivabradine for Rate Control in Permanent Atrial Fibrillation","status":"COMPLETED","sponsor":"Yale University","startDate":"2019-06-15","conditions":["Atrial Fibrillation","Atrial Fibrillation, Persistent"],"enrollment":4,"completionDate":"2019-09-17"},{"nctId":"NCT03182725","phase":"PHASE3","title":"Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2018-02-06","conditions":["Postural Orthostatic Tachycardia Syndrome"],"enrollment":37,"completionDate":"2020-05-08"},{"nctId":"NCT04549805","phase":"","title":"Troponin to Risk Stratify Patients for Computed Tomography Coronary Angiography","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-12-04","conditions":["Coronary Artery Disease","Acute Coronary Syndrome"],"enrollment":250,"completionDate":"2020-10-06"},{"nctId":"NCT04405804","phase":"PHASE2","title":"Early Administration of Ivabradine in Children With Heart Failure","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2020-06-20","conditions":["Acute Heart Failure","Dilated Cardiomyopathy"],"enrollment":9,"completionDate":"2021-05"},{"nctId":"NCT03105219","phase":"PHASE3","title":"IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease","status":"WITHDRAWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2017-07-01","conditions":["Diabetic Kidney Disease"],"enrollment":0,"completionDate":"2021-05-30"},{"nctId":"NCT04580342","phase":"PHASE2","title":"Ivabradine Versus Propranolol for Induced Hypotension in Endoscopic Sinus Surgery","status":"UNKNOWN","sponsor":"Ahmed talaat ahmed aly","startDate":"2020-10-15","conditions":["Hypotension"],"enrollment":60,"completionDate":"2021-01-30"},{"nctId":"NCT00825123","phase":"PHASE4","title":"Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals","status":"TERMINATED","sponsor":"Bayside Health","startDate":"2008-10","conditions":["Central Arterial Pressure"],"enrollment":2,"completionDate":"2011-11-08"},{"nctId":"NCT00815100","phase":"PHASE4","title":"Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Hospital Universitario de Canarias","startDate":"2009-04","conditions":["Acute Coronary Syndromes"],"enrollment":27,"completionDate":"2011-09-07"},{"nctId":"NCT04308031","phase":"PHASE3","title":"Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction","status":"UNKNOWN","sponsor":"Chun-Yao Huang","startDate":"2018-08-26","conditions":["Atrial Fibrillation","Ivabradine","Heart Failure"],"enrollment":100,"completionDate":"2020-12-31"},{"nctId":"NCT01868880","phase":"PHASE4","title":"Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing","status":"WITHDRAWN","sponsor":"Policlinico Casilino ASL RMB","startDate":"2016-02","conditions":["Heart Rate Control in ICD Patients With Heart Failure"],"enrollment":0,"completionDate":"2023-12"},{"nctId":"NCT02441218","phase":"PHASE3","title":"Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2006-09","conditions":["Chronic Heart Failure"],"enrollment":6505,"completionDate":"2010-04"},{"nctId":"NCT02247245","phase":"NA","title":"The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2014-09","conditions":["Chronic Heart Failure","Atrial Fibrillation","Arrhythmia, Sinus"],"enrollment":40,"completionDate":"2015-09"},{"nctId":"NCT04208594","phase":"NA","title":"Efficacy of Ivabradine Versus Propranolol Premedication During Hypotensive Anesthesia in Endoscopic Sinus Surgery","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2019-12-11","conditions":["Ivabradine","Propranolol","Hypotensive Anesthesia"],"enrollment":50,"completionDate":"2020-05"},{"nctId":"NCT04030546","phase":"PHASE3","title":"Ivabradine to Prevent Anthracycline-induced Cardiotoxicity","status":"UNKNOWN","sponsor":"Vilnius University","startDate":"2019-06-01","conditions":["Patients With Cancer"],"enrollment":128,"completionDate":"2020-12-31"},{"nctId":"NCT02827500","phase":"PHASE4","title":"Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-07","conditions":["Heart Failure"],"enrollment":104,"completionDate":"2018-10-15"},{"nctId":"NCT03387605","phase":"PHASE4","title":"Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine","status":"UNKNOWN","sponsor":"Loyola University","startDate":"2018-03-15","conditions":["Heart Failure","Cardiogenic Shock","Tachycardia"],"enrollment":40,"completionDate":"2020-06"},{"nctId":"NCT03830957","phase":"NA","title":"Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker","status":"UNKNOWN","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-11-26","conditions":["Heart Failure","CT Angiography","Ischemic Cardiomyopathy","Non-ischemic Cardiomyopathy","Heart Failure, Systolic","Heart Failure，Congestive","Heart Failure, Diastolic","Heart Rate Low"],"enrollment":200,"completionDate":"2019-12"},{"nctId":"NCT03650205","phase":"NA","title":"Ivabradine to Prevent Anthracycline-induced Cardiotoxicity","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2019-01-22","conditions":["Neoplasms","Heart Failure","Cardiotoxicity","Chemotherapy Effect","Oncology"],"enrollment":160,"completionDate":"2021-12-01"},{"nctId":"NCT03866395","phase":"PHASE4","title":"Effects of Ivabradine on Residual Myocardial Ischemia After PCI","status":"COMPLETED","sponsor":"Azienda Policlinico Umberto I","startDate":"2015-03-05","conditions":["Angina Pectoris, Stable"],"enrollment":28,"completionDate":"2017-03-07"},{"nctId":"NCT03405831","phase":"PHASE4","title":"Effect of Ivabradine on Exercise Capacity After Heart Transplantation","status":"UNKNOWN","sponsor":"Finn Gustafsson","startDate":"2018-04-17","conditions":["Cardiac Allograft Vasculopathy","Transplanted Heart Complication"],"enrollment":35,"completionDate":"2019-12"},{"nctId":"NCT03619187","phase":"PHASE3","title":"An Interventional Study to Evaluate the Effect of Ivabradine on Exercise Capacity in Heart Transplant Recipients","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2018-11-02","conditions":["Heart Transplantation, Elevated Resting Heart Rate"],"enrollment":0,"completionDate":"2020-02-19"},{"nctId":"NCT03710057","phase":"","title":"Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2016-12-01","conditions":["Chronic Heart Failure"],"enrollment":50,"completionDate":"2017-05-15"},{"nctId":"NCT03701880","phase":"NA","title":"Early Use of Ivabradine in Heart Failure","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2018-09-16","conditions":["Heart Failure With Reduced Ejection Fraction","Decompensated Heart Failure"],"enrollment":50,"completionDate":"2019-12-23"},{"nctId":"NCT02507050","phase":"PHASE4","title":"Ivabradine and Post-revascularisation Microcirculatory Dysfunction","status":"WITHDRAWN","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2016-03","conditions":["Coronary Artery Disease","Angina"],"enrollment":0,"completionDate":"2016-03"},{"nctId":"NCT03245996","phase":"PHASE4","title":"The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker","status":"COMPLETED","sponsor":"Tartu University Hospital","startDate":"2015-06","conditions":["Aortic Blood Pressure"],"enrollment":27,"completionDate":"2016-09"},{"nctId":"NCT00143507","phase":"PHASE3","title":"The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2004-12","conditions":["Coronary Disease","Ventricular Dysfunction, Left"],"enrollment":10917,"completionDate":"2008-02"},{"nctId":"NCT03485482","phase":"PHASE3","title":"Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2018-03-01","conditions":["Cardiovascular Diseases"],"enrollment":18,"completionDate":"2018-03-23"},{"nctId":"NCT02764970","phase":"","title":"Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-02","conditions":["Bradycardia"],"enrollment":112,"completionDate":"2016-01"},{"nctId":"NCT00202566","phase":"PHASE3","title":"Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2005-06","conditions":["Angina Pectoris"],"enrollment":750,"completionDate":"2007-10"},{"nctId":"NCT03437369","phase":"PHASE4","title":"Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock","status":"UNKNOWN","sponsor":"Hospital Universitario Ramon y Cajal","startDate":"2018-05","conditions":["Cardiogenic Shock"],"enrollment":22,"completionDate":"2019-10"},{"nctId":"NCT02294292","phase":"NA","title":"Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2014-07-01","conditions":["Diastolic Dysfunction","Chronic Liver Disease"],"enrollment":189,"completionDate":"2016-08-31"},{"nctId":"NCT03367026","phase":"NA","title":"Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2018-01-01","conditions":["Sepsis, Severe"],"enrollment":70,"completionDate":"2021-06-30"},{"nctId":"NCT01796093","phase":"","title":"Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function","status":"COMPLETED","sponsor":"Cocco, Giuseppe, M.D.","startDate":"2008-04","conditions":["Heart Failure","Atrial Fibrillation"],"enrollment":42,"completionDate":"2012-02"},{"nctId":"NCT02236247","phase":"PHASE1,PHASE2","title":"Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2013-05","conditions":["Decompensated Heart Failure"],"enrollment":50,"completionDate":"2017-08"},{"nctId":"NCT01657136","phase":"PHASE3","title":"Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia","status":"COMPLETED","sponsor":"Policlinico Casilino ASL RMB","startDate":"2013-09","conditions":["Inappropriate Sinus Tachycardia"],"enrollment":20,"completionDate":"2016-09"},{"nctId":"NCT02086422","phase":"NA","title":"Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure","status":"UNKNOWN","sponsor":"The Leeds Teaching Hospitals NHS Trust","startDate":"2013-07","conditions":["Chronic Heart Failure"],"enrollment":0,"completionDate":""},{"nctId":"NCT02681978","phase":"PHASE4","title":"Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2014-02","conditions":["Coronary Artery Disease"],"enrollment":70,"completionDate":"2015-07"},{"nctId":"NCT02008110","phase":"PHASE4","title":"Carbohydrate Antigen 125-guided Therapy in Heart Failure","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2011-12","conditions":["Heart Failure"],"enrollment":360,"completionDate":"2015-05"},{"nctId":"NCT02623569","phase":"PHASE2","title":"To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina","status":"UNKNOWN","sponsor":"Xintong Pharmacy Company","startDate":"2014-10","conditions":["Angina Pectoris"],"enrollment":336,"completionDate":"2017-06"},{"nctId":"NCT02354573","phase":"NA","title":"The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2011-12","conditions":["Heart Failure"],"enrollment":121,"completionDate":"2014-01"},{"nctId":"NCT00757055","phase":"PHASE2","title":"If Channel Blockade With Ivabradine in Patients With Diastolic Heart Failure","status":"WITHDRAWN","sponsor":"St Vincent's University Hospital, Ireland","startDate":"2012-12","conditions":["Diastolic Heart Failure"],"enrollment":0,"completionDate":"2014-01"},{"nctId":"NCT01755663","phase":"PHASE4","title":"Comparison of Efficacy of Ivabradine Versus Metoprolol","status":"UNKNOWN","sponsor":"Col. Suthee Panichkul","startDate":"2014-12","conditions":["Coronary Artery Disease"],"enrollment":60,"completionDate":"2015-12"},{"nctId":"NCT01178528","phase":"PHASE3","title":"Heart Rate Reduction in Heart Failure","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2009-09","conditions":["Heart Failure"],"enrollment":121,"completionDate":"2010-10"},{"nctId":"NCT02188082","phase":"PHASE2,PHASE3","title":"Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2014-05","conditions":["Chronic Systolic Heart Failure"],"enrollment":336,"completionDate":""},{"nctId":"NCT02166060","phase":"PHASE4","title":"Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy","status":"UNKNOWN","sponsor":"Medical University of Warsaw","startDate":"2014-08","conditions":["Heart Failure"],"enrollment":60,"completionDate":"2016-10"},{"nctId":"NCT02046044","phase":"PHASE4","title":"Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction","status":"UNKNOWN","sponsor":"Kocaeli University","startDate":"2014-01","conditions":["Heart Failure"],"enrollment":60,"completionDate":"2014-10"},{"nctId":"NCT01699776","phase":"PHASE4","title":"Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure","status":"COMPLETED","sponsor":"Cocco, Giuseppe, M.D.","startDate":"2008-04","conditions":["Cardiac Failure"],"enrollment":22,"completionDate":"2012-02"},{"nctId":"NCT01039389","phase":"NA","title":"Promotion of Coronary Collateral Function by Ivabradine-Induced Bradycardia in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2009-10","conditions":["Coronary Artery Disease"],"enrollment":43,"completionDate":"2013-03"},{"nctId":"NCT01804010","phase":"PHASE1","title":"Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2007-05","conditions":["Healthy Individual"],"enrollment":48,"completionDate":"2007-11"},{"nctId":"NCT01768585","phase":"PHASE4","title":"Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease","status":"UNKNOWN","sponsor":"University Hospital, Saarland","startDate":"2012-12","conditions":["Coronary Artery Disease","Coronary Arteriosclerosis"],"enrollment":50,"completionDate":"2014-12"},{"nctId":"NCT01761825","phase":"PHASE2","title":"The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2012-12","conditions":["Postural Tachycardia Syndrome"],"enrollment":20,"completionDate":""},{"nctId":"NCT01425164","phase":"PHASE4","title":"Ischemia In Hemodialysed Patients: Ivabradine Versus Carvedilol","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2011-01","conditions":["Coronary Heart Disease","Angina","Hemodialysis"],"enrollment":220,"completionDate":"2012-06"},{"nctId":"NCT01364077","phase":"PHASE4","title":"Ivabradine in Hemodialysed Patients With Increased Heart Rate","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2010-01","conditions":["High Heart Rate"],"enrollment":100,"completionDate":""},{"nctId":"NCT01365286","phase":"PHASE4","title":"HR-lowering Efficacy and Respiratory Safety of Ivabradine in Patients With Obstructive Airway Disease","status":"COMPLETED","sponsor":"Medical University of Lodz","startDate":"2009-05","conditions":["Asthma, Chronic Obstructive Pulmonary Disease (COPD)"],"enrollment":40,"completionDate":"2011-01"},{"nctId":"NCT01373619","phase":"PHASE4","title":"Heart Failure With Normal Ejection Fraction (HFNEF) in Hemodialysed Patients: Beneficial Effect of Ivabradine","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2010-01","conditions":["Heart Failure"],"enrollment":150,"completionDate":"2012-01"},{"nctId":"NCT01029223","phase":"PHASE4","title":"The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals","status":"WITHDRAWN","sponsor":"Bayside Health","startDate":"2008-10","conditions":["Blood Pressure"],"enrollment":42,"completionDate":"2011-12"},{"nctId":"NCT01022463","phase":"PHASE3","title":"Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm","status":"COMPLETED","sponsor":"Govind Ballabh Pant Hospital","startDate":"2009-11","conditions":["Mitral Stenosis"],"enrollment":50,"completionDate":"2010-10"},{"nctId":"NCT01186783","phase":"PHASE2","title":"Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine","status":"UNKNOWN","sponsor":"Martin-Luther-Universität Halle-Wittenberg","startDate":"2010-05","conditions":["Multiple Organ Dysfunction Syndrome"],"enrollment":70,"completionDate":"2012-05"},{"nctId":"NCT00865917","phase":"PHASE2","title":"Cardiovascular Effects of Selective I(f)-Channel Blockade","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2008-11","conditions":["Postural Orthostatic Tachycardia Syndrome"],"enrollment":40,"completionDate":"2010-12"}],"_emaApprovals":[{"date":"2005-10-25","status":"Authorised","company":"Les Laboratoires Servier"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Solution, Tablet","formulations":[{"form":"SOLUTION","route":"ORAL","productName":"Corlanor"},{"form":"TABLET, FILM COATED","route":"ORAL","productName":"Corlanor"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"20884","NDDF":"011156","UNII":"3H48L0LPZQ","CHEBI":"CHEBI:85969","VANDF":"4034416","INN_ID":"7523","RXNORM":"1649479","UMLSCUI":"C0257190","chemblId":"CHEMBL471737","ChEMBL_ID":"CHEMBL471737","KEGG_DRUG":"D07165","DRUGBANK_ID":"DB09083","PUBCHEM_CID":"132999","SNOMEDCT_US":"420906000","IUPHAR_LIGAND_ID":"2357","SECONDARY_CAS_RN":"148849-67-6","MESH_DESCRIPTOR_UI":"D000077550"},"formularyStatus":[],"originalProduct":{"form":"SOLUTION","route":"ORAL","company":"Amgen Inc","brandName":"Corlanor","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Amgen","relationship":"Original Developer"},{"period":"2005","companyName":"Les Laboratoires Servier","relationship":"EMA Licensee"},{"period":"2019","companyName":"Ono Pharmaceutical Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","clearance":"10.27 mL/min/kg","fractionUnbound":"0.28%","volumeOfDistribution":"1.66 L/kg"},"publicationCount":1877,"therapeuticAreas":["Cardiovascular"],"_revenueScrapedAt":"2026-03-31 10:32:25.075465+00","atcClassification":{"source":"DrugCentral","atcCode":"C01EB17","allCodes":["C01EB17","C07FX05","C07FX06"]},"biosimilarFilings":[],"originalDeveloper":"Amgen Inc","recentPublications":[{"date":"2026 Mar 19","pmid":"41901349","title":"Ivabradine Attenuates Experimental Hepatic Fibrosis by Modulating Inflammatory and Apoptotic Signaling Pathways.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 21","pmid":"41863817","title":"Comparative Effectiveness of Ivabradine Versus Digoxin in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease: A Real-World Multicenter Cohort Study.","journal":"Cardiorenal medicine"},{"date":"2026 Mar 18","pmid":"41845224","title":"Potential use of ivabradine in postoperative junctional ectopic tachycardia: a systematic review and single-arm meta-analysis.","journal":"BMC cardiovascular disorders"},{"date":"2026 Mar 13","pmid":"41823892","title":"Cost-effectiveness of Add-On Ivabradine Versus Standard Pharmacotherapy in the Treatment of Heart Failure in Vietnam: An Analysis From a Health System Perspective.","journal":"Value in health regional issues"},{"date":"2026 Mar 12","pmid":"41817681","title":"Personalized management of angina and heart failure in clinical practice in the Middle East: a narrative review.","journal":"Journal of comparative effectiveness research"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Amgen Inc","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2005-10-25T00:00:00.000Z","mah":"Les Laboratoires Servier","brand_name_local":"Corlentor","application_number":"EMEA/H/C/000598"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2005-10-25T00:00:00.000Z","mah":"Les Laboratoires Servier","brand_name_local":"Procoralan","application_number":"EMEA/H/C/000597"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2005-10-25T00:00:00.000Z","mah":"Les Laboratoires Servier","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-15T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-15T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":"CORLANOR","application_number":"NDA206143"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2015-09-08T00:00:00.000Z","mah":"\"Anpharm\" Przedsiębiorstwo Farmaceutyczne S.A.","brand_name_local":"Ivabradine Anpharm","application_number":"EMEA/H/C/004187"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2016-11-11T00:00:00.000Z","mah":"Zentiva, k.s.","brand_name_local":"Ivabradine Zentiva","application_number":"EMEA/H/C/004117"},{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2016-11-11T00:00:00.000Z","mah":"JensonR+ Limited","brand_name_local":"Ivabradine JensonR","application_number":"EMEA/H/C/004217"},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2017-05-22T00:00:00.000Z","mah":"Accord Healthcare S.L.U.","brand_name_local":"Ivabradine Accord","application_number":"EMEA/H/C/004241"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2019-04-22T00:00:00.000Z","mah":"AMGEN INC","brand_name_local":"CORLANOR","application_number":"NDA209964"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2019-09-20T00:00:00.000Z","mah":"Ono Pharmaceutical Co., Ltd.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-10-05T00:00:00.000Z","mah":"ANNORA PHARMA","brand_name_local":null,"application_number":"ANDA213366"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-11-29T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA213442"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-28T00:00:00.000Z","mah":"MSN","brand_name_local":null,"application_number":"ANDA213483"},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":8,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:12:09.955877+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}